Clinical Trial Update: E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating E6201 in combination with dabrafenib for metastatic melanoma with brain metastases; study terminated with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases of Malignant Melanoma
• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• E6201

Snippet

Sponsor: Spirita Oncology, LLC | Conditions: Malignant Melanoma, Brain Metastases | Phase 1 | Status: TERMINATED | Results posted: 2022-05-20